Brain Cancer
Midline Glioblastoma
Female, 36 years
Patient Internal 434626791
ICD-10 code
C71.7 Malignant Neoplasm of Brain Stem
Diagnosis (Incl. Metastases/Stage) and Year
May 2021
Midline Glioma, WHO Grade 4, likely H3K27M Mutation, IDH1/2 mutations not detected, TERT (-).
Disease progression in June 2023.
Previous Treatment
Surgery, Radiation Therapy, Chemotherapy (Temozolomide), Chemotherapy (Lomustine).
Prognosis and Survival Expectation
The prognosis remains poor, with a median survival of ~14 months from diagnosis.
Treatment Provided
Autologous DCV (4 doses) and CIK (16 doses) over a period of 14 months.
Patient Survival/Condition and Year
Date of Review: 15/11/2023
The patient has survived for 29 months. It can be concluded that the addition of Immunotherapy, alongside Surgery, Radiation Therapy and Chemotherapy, has benefited in disease stabilisation and extended survival by an estimate of 15 months so far.
